News for Compass Therapeutics, Inc. (CMPX)

**media[582593]**

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Compass Therapeutics, Inc.

Net Loss: Reported a net loss of $49.4 million for 2024, compared to $42.5 million in 2023, reflecting increased investment in R&D.Earnings Per Share (EPS): Re

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (B

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Explore Compass Therapeutics' tovecimig trials, upcoming Phase 3 BTC data, and market insights.

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiation...

On December 31, 2024, MPM BIOIMPACT LLC (Trades, Portfolio)executed a significant transaction involving Compass Therapeutics Inc. The firm added 2,926,002 shar

On December 31, 2024, ADAGE CAPITAL PARTNERS GP, L.L.C. (Trades, Portfolio) executed a notable transaction involving Compass Therapeutics Inc (CMPX). The firm r

Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Stocks Analysis by MarketBeat.com (Nathan Reiff) covering: Allot Ltd, AeroVironment Inc, Vodafone Group PLC ADR, Compass Therapeutics, Inc.. Read MarketBeat.com (Nathan Reiff)'s latest article on Investing.com

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Compass Therapeutics Inc (NASDAQ:CMPX) stands ...

This is our list of the best penny stocks to watch, based on a review of stocks that had positive performance over the last 30 days.

Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.

CMPX is stable with $36.8 million in cash and $98.6 million in marketable securities, ensuring a runway through 2025 without major cash concerns. Read more here.

BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ( CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing propriet

Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE,...

Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers,...